BioSpace News Archive

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced new data from a subset of patients in an ongoing Phase 1 study of its lead program, P-BCMA-ALLO1.

Adela, Inc. presented initial results demonstrating the ability of its MRD assay to predict recurrence in head & neck cancer, at the American Association for Cancer Research (AACR) Annual Meeting from April 5-10, 2024.

Immunitas Therapeutics (“Immunitas”) today presented preclinical data supporting the combination potential of IMT-009 with anti-PD1 immunotherapy at the American Association for Cancer Research Annual Meeting (AACR 2024) in San Diego, California.

Serum Detect, Inc., a cancer diagnostics company advancing new technologies for early detection of cancer, today announced the presentation of new data at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

EpiBiologics, a preclinical stage company advancing new bispecific antibody therapeutics for extracellular protein degradation, is presenting data today on its EpiTAC protein degraders in oncology demonstrating robust in vivo anti-tumor activity and survival benefit.

Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, presented preclinical data from MYTX-011, its investigational cMET-targeting ADC, at the American Association for Cancer Research (AACR) Annual Meeting.

MaaT Pharma (EURONEXT: MAAT – the “Company”) presented new in vitro data characterizing the metabolites produced by MaaT034 and their impact on immune modulation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.

Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced a research collaboration with the Food and Drug Administration (FDA).

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced that preclinical data for the company’s lead program, NST-628, were featured in an oral presentation in the “New Drugs on the Horizon” series at the American Association for Cancer Research (AACR) Annual Meeting.

Quanta Therapeutics announced the presentation of QTX3544, a multi-KRAS inhibitor with G12V-preferring activity (G12V+ multi-KRAS), in a late-breaking poster presentation session at the American Association of Cancer Research (AACR) Annual Meeting.